This page shows the latest Tremfya news and features for those working in and with pharma, biotech and healthcare.
On paper Skyrizi is actually a closer competitor to Johnson &Johnson's Tremfya (guselkumab), which also targets IL-23, but there’s little doubt that – sales-wise at least – Cosentyx is ... Tremfya, which made $742m for J&J in the first nine months
J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... loss. If it can win approval, Tremfya will become the first selective IL-23
This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).
If approved by the EMA, Tremfya will be the first selective IL-23 inhibitor for people with active PsA in the EU. ... Some analysts suggest Skyrizi matches Tremfya for efficacy but offers less frequent dosing during the maintenance phase of treatment, as
Growth for immunology therapy Stelara (ustekinumab) and blood cancer drugs Imbruvica (ibrutinib) and Darzalex (daratumumab) – plus Stelara follow-up Tremfya (guselkumab) – outweighed the effect of generic competition to older prostate cancer
The application to the FDA is based on the top line results from the pivotal phase 3 trials of Tremfya, DISCOVER-1 and DISCOVER-2. ... weeks. These factors could damage Tremfya’s uptake in this indication, if approved, but it’s already established
More from news
Approximately 9 fully matching, plus 18 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...